SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Ionis Pharmaceuticals (IONS)
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
4676 121 0 IONS
Emcee:  Keith Fauci Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
4526<They are probably planing on doing a longer trial after some more tox studiemarc ultra-11/14/2009
4525Thanks, makes perfect sense. Sort out any issues during PhII before designing lIan@SI110/23/2009
4524Ian, sorry for not being clear on this: time frame in that trial was 13 weeks anidos110/23/2009
4523Given that it takes about 3 months to replace one's haemoglobin, the companyIan@SI-10/22/2009
4522Note that ISIS 113715 didn't (stat-sig) reduce HbA1C, but perhaps it takes midos-10/22/2009
4521UPDATE 1-Isis Pharma diabetes drug shows promise in mid-stage Wed Oct 21, 2009 4bob zagorin-10/21/2009
4520Hmmm, they seem to have disappeared. Many thanks to SI Admin(Dave). ;-)Ian@SI15/25/2009
4519Anyone think the last 4 posts were by the same person?? vbgThe Ox25/22/2009
4518There's also this story... eurekalert.org Public Release: 20-May-2009 OligoIan@SI-5/20/2009
4517Elevated Transaminase levels may be an indicator of liver damage. Most humans oIan@SI-5/20/2009
4516There were 5 more patients who discontinued but from different reasons.idos-5/20/2009
4515"One patient discontinued due to elevations in liver transaminases." fred hayes-5/20/2009
4514Any thoughts on on the selloff on what seems to be good news?biofisher-5/20/2009
4513Genzyme and Isis Announce that Mipomersen Phase 3 Study in Patients with HomozygLJM-5/20/2009
4512Isis and Alnylam Form New Collaboration to Develop Single-Stranded RNAi TechnoloLJM-4/29/2009
4511ISIS: Collins Stewart's conversations with clinical investigators indicate tbob zagorin-3/20/2009
4510ISIS Pharm: Abbott exercises its option to acquire Ibis Biosciences, a subsidiarLJM-12/17/2008
4509Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate CanLJM-12/3/2008
4508Article regarding ROSG and research on heart failure in mice-- news.yahoo.com MJ-11/30/2008
4507Isis Announces Award of Up to $8.4 Million in New Government Grants and Contractbob zagorin-10/3/2008
4506Rosetta Genomics Announces Transfer of MicroRNA-based Liver Therapeutics Projectbob zagorin-9/23/2008
4505Zacks Analyst Interview Highlights: Isis Pharmaceuticals, Genzyme and Abbott Labbob zagorin-9/23/2008
4504ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research ibob zagorin-9/22/2008
4503Smarticles to Deliver Isis CD40 Antisense! novosom.com >> Novosom AG acqubob zagorin-8/26/2008
4502www1.investorvillage.combob zagorin-8/24/2008
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News